Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK‐positive non‐small cell lung cancer: A retrospective, real‐world study

Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK‐positive non‐small cell lung cancer: A retrospective, real‐world study

Abstract Objectives Crizotinib has demonstrated good efficacy in patients with anaplastic lymphoma kinase (ALK)‐positive non‐small cell lung cancer (NSCLC). Continuing crizotinib therapy beyond progressive disease (CBPD) can achieve ongoing survival benefit in real‐world clinical practice. In terms...

書誌詳細
主要な著者:	Guangjian Yang, Di Ma, Haiyan Xu, Lu Yang, Junling Li, Puyuan Xing, Xuezhi Hao, Yan Wang
フォーマット:	論文
言語:	English
出版事項:	Wiley 2019-10-01
シリーズ:	Cancer Medicine
主題:	anaplastic lymphoma kinase inhibitor crizotinib crizotinib continuation beyond progressive disease non‐small cell lung cancer treatment duration
オンライン･アクセス:	https://doi.org/10.1002/cam4.2420

類似資料

Three years sustained complete remission achieved in a primary refractory ALK-positive anaplastic T large cell lymphoma treated with crizotinib
著者:: Carolina Valeria Mahuad, 等
出版事項: (2016-06-01)

Clinical Efficacy of Crizotinib in Treatment of Patients with Advanced NSCLC
著者:: Emei GAO, 等
出版事項: (2016-03-01)

The Use of Crizotinib in Sclerosing Epithelioid Fibrosarcoma with ALK Mutation: A Case Report
著者:: Ahmed Badran, 等
出版事項: (2023-08-01)

Treatment of Patients with ALK Gene Rearranged Non-small Cell Lung Cancer  after Resistance to Crizotinib
著者:: Tao JIANG, 等
出版事項: (2015-02-01)

ROS1 rearrangement and response to crizotinib in Stage IV non-small cell lung cancer
著者:: Moushumi Suryavanshi, 等
出版事項: (2017-01-01)

Efficacy of different sequential patterns after crizotinib progression in advanced anaplastic lymphoma kinase‐positive non–small cell lung cancer
著者:: Xiya Ma, 等
出版事項: (2022-06-01)

Crizotinib in treatment of lung cancer
著者:: Arpita Singh, 等
出版事項: (2017-01-01)

Unusual Late Relapse of ALK-Positive Anaplastic Large Cell Lymphoma Successfully Cleared Using the ALK-Inhibitor Crizotinib: Case Report
著者:: Dennis Christoph Harrer, 等
出版事項: (2020-10-01)

Disease Flare after Discontinuation of Crizotinib in Anaplastic Lymphoma Kinase-Positive Lung Cancer
著者:: Yuka Kuriyama, 等
出版事項: (2013-08-01)

Hexokinases II‐mediated glycolysis governs susceptibility to crizotinib in ALK‐positive non‐small cell lung cancer
著者:: Caiyu Lin, 等
出版事項: (2021-12-01)

Real World Experience of Crizotinib in 104 Patients With ALK Rearrangement Non-small-cell Lung Cancer in a Single Chinese Cancer Center
著者:: Chang Liu, 等
出版事項: (2019-10-01)

Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer
著者:: Chan-Young Ock, 等
出版事項: (2019-09-01)

The Dual Role of Autophagy in Crizotinib-Treated ALK<sup>+</sup> ALCL: From the Lymphoma Cells Drug Resistance to Their Demise
著者:: Estelle Espinos, 等
出版事項: (2021-09-01)

Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells
著者:: Muhammad Wasi Alam, 等
出版事項: (2019-07-01)

Clinical outcome, long‐term survival and tolerability of sequential therapy of first‐line crizotinib followed by alectinib in advanced ALK+NSCLC: A multicenter retrospective analysis in China
著者:: Zihua Zou, 等
出版事項: (2022-01-01)

Whole-process Management of Treatment of Advanced ALK Positive Non-small Cell Lung Cancer: A Case Report
著者:: Henan BAI, 等
出版事項: (2021-08-01)

Crizotinib for recurring non‐small‐cell lung cancer with EML4‐ALK fusion genes previously treated with alectinib: A phase II trial
著者:: Daijiro Harada, 等
出版事項: (2021-03-01)

Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials
著者:: Scott N. Gettinger, MD, 等
出版事項: (2022-09-01)

Real‐world outcome of crizotinib for anaplastic lymphoma kinase‐positive lung cancer: Multicenter retrospective analysis in South Korea
著者:: Da Som Jeon, 等
出版事項: (2024-02-01)

Alectinib-Induced Alopecia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
著者:: Tomonobu Koizumi, 等
出版事項: (2016-04-01)

Crizotinib-Associated Renal Cysts: A Case Series
著者:: Garima Suman, 等
出版事項: (2019-07-01)

Efficacy of crizotinib retreatment after crizotinib-related interstitial lung disease in a patient with ROS1-rearranged advanced lung adenocarcinoma: A case report and potential crizotinib retreatment strategy
著者:: Woo Kyung Ryu, 等
出版事項: (2022-10-01)

A Case of Orbital Metastasis as Disease Progression of Anaplastic Lymphoma Kinase-Positive Lung Cancer Treated with Crizotinib
著者:: Yoshihiko Sakata, 等
出版事項: (2015-01-01)

Efficacy and safety of crizotinib in patients with anaplastic lymphoma kinase-positive advanced-stage non-small-cell lung cancer
著者:: Mohieldin A, 等
出版事項: (2018-11-01)

Alectinib Induced Regression of Renal and Hepatic Cysts Caused by Crizotinib
著者:: Di Marino P, 等
出版事項: (2020-03-01)

Molecular epidemiological study of microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene using immunohistochemistry as a cost effective alternative to fluorescence in situ hybridization for Indian patients with adenocarcinoma lung
著者:: Anurag Mehta, 等
出版事項: (2017-01-01)

Clinical characteristics and risk factors of drug‐induced lung injury by ALK tyrosine kinase inhibitors: A single center retrospective analysis
著者:: Ken Koshikawa, 等
出版事項: (2020-06-01)

Successful Management of Crizotinib-Induced Neutropenia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Case Report
著者:: Jun Osugi, 等
出版事項: (2016-01-01)

Clinical Efficacy of Crizotinib in Advanced ALK Positive  Non-small Cell Lung Cancer
著者:: Jing ZHAO, 等
出版事項: (2015-10-01)

Modern treatment of ALK-positive non-small cell lung cancer
著者:: D. A. Kharagezov, 等
出版事項: (2022-06-01)

Identification of a novel ALK variant intrinsically resistant to crizotinib
著者:: Ullas Batra, 等
出版事項: (2020-12-01)

Efficacy and Safety of Crizotinib in Advanced or Recurrent  ALK-positive Non-small Cell Lung Cancer
著者:: Xiaoyan LI, 等
出版事項: (2019-08-01)

Development of crizotinib-associated renal cyst in a non-small cell lung cancer patient with ALK fusion: a case report and review of the literature
著者:: Peng Zhang, 等
出版事項: (2024-04-01)

Case report: The utilization of crizotinib and brentuximab vedotin as a bridge to autologous stem cell transplantation and followed by CD30-directed CAR-T cell therapy in relapsed/refractory ALK+ ALCL
著者:: Wanying Liu, 等
出版事項: (2024-02-01)

Alectinib versus crizotinib in ALK‐positive advanced non‐small cell lung cancer and comparison of next‐generation TKIs after crizotinib failure: Real‐world evidence
著者:: Yurong Wang, 等
出版事項: (2022-12-01)

Long‐term response to crizotinib in a 17‐year‐old boy with treatment‐naïve ALK‐positive non‐small‐cell lung cancer
著者:: Giacomina Megaro, 等
出版事項: (2022-03-01)

Alectinib Versus Crizotinib in Asian Patients With Treatment-Naïve Advanced ALK-Positive NSCLC: Five-Year Update From the Phase 3 ALESIA Study
著者:: Caicun Zhou, MD, PhD, 等
出版事項: (2024-09-01)

Case report: ALK-positive histiocytosis presented as bilateral synchronous breast masses with long-term remission on crizotinib
著者:: Yuhang Zhou, 等
出版事項: (2023-11-01)

Efficacy of crizotinib therapy for a patient with non-small cell lung cancer with ALK gene rearrangement – case report and review of current therapeutic options
著者:: Julia Barbara Bargieł, 等
出版事項: (2021-09-01)

A Case of Lung Adenocarcinoma Harboring a Rare LOC285000-ALK-NCK2 Gene Fusion Identified by Next-Generation Sequencing With Long-Term Response to Crizotinib
著者:: Min Zhang, MBBS, 等
出版事項: (2021-02-01)